Alopecia

Posts

Global Androgenic Alopecia Drug Market 2018

Global Androgenic Alopecia Drug Market 2018

Global Androgenic Alopecia Drug Market 2018 Analysis and Overview by QY Market Research

QY Market Research has recently published the latest report titled Global Androgenic Alopecia Drug Market Report 2018. Androgenic Alopecia Drug Market report gives complete global coverage of Androgenic Alopecia Drug market data from 2013 to 2018.

This Androgenic Alopecia Drug report starts with the review of Androgenic Alopecia Drug industry chain structure and defines the Androgenic Alopecia Drug business growth rate, trend, current status, investigates global Androgenic Alopecia Drug market share/volume and forecast up to 2023.

Worldwide Androgenic Alopecia Drug market report analyzes world’s main regions and additionally provides Androgenic Alopecia Drug industry top player’s Profiles/Analysis (Allergan,Inc., Histogen,Inc., R-TechUeno,Ltd., HygeiaTherapeutics,Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd. ), regional coverage, product insights, Androgenic Alopecia Drug product types and product application insights.

Global Androgenic Alopecia Drug Market esteemed at XX million USD in last year(2017) and Androgenic Alopecia Drug market report expected it to reach XX million USD in forthcoming years during(2018-2023). The Worldwide Androgenic Alopecia Drug Market volume is predicted to boost a spectacular growth at XXX% of CAGR during the forecast duration.

The years considered to anticipate the market size of Androgenic Alopecia Drug are Base Year: 2017, Estimated Year: 2018, History Period/Year(last 5 years Historical data): 2013-2017, and Forecast Period/Year 2018 to 2023.

Top Manufacturers/Companies Included in Global Androgenic Alopecia Drug Market Report are: Allergan, Inc., Histogen, Inc., R-TechUeno, Ltd., HygeiaTherapeutics, Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd.

Androgenic Alopecia Drug Industry Regional Analysis and Market Insights:

Regionally Androgenic Alopecia Drug market report isolated globally into some major key Regions, with revenue (million USD), Androgenic Alopecia Drug sales data (K Units), Androgenic Alopecia Drug market share (%) and growth rate of Androgenic Alopecia Drug industry for mentioned regions.

The Androgenic Alopecia Drug study report contains Androgenic Alopecia Drug market in North America(United States, Canada, Mexico), Androgenic Alopecia Drug business in Central & South America(Argentina, Chile, Brazil), Androgenic Alopecia Drug industry in Europe(UK, Spain, Germany, Italy, France, and Russia), Androgenic Alopecia Drug marketplace in the Middle East & Africa(Turkey, Egypt, Saudi Arabia, and South Africa) and Androgenic Alopecia Drug market in Asia-Pacific(India, China, Japan, South Korea, Indonesia, Singapore, Australia). The Androgenic Alopecia Drug Report additionally gives Key Partners with Androgenic Alopecia Drug producer, Androgenic Alopecia Drug Subcomponent Makers, Androgenic Alopecia Drug Traders/Wholesalers/Distributors, Downstream Vendors and Androgenic Alopecia Drug Industry Unions.

On the basis of Product Type, the Global Androgenic Alopecia Drug industry report shows the product price (USD/Unit), sales volume (K Units), Androgenic Alopecia Drug market share (%), production, Androgenic Alopecia Drug revenue (Million USD), and growth rate of each type, mainly split into; RK-023, Refagro, RCH-01, SM-04554, HYG-440, Others.

On the basis of Applications/end users, the Global Androgenic Alopecia Drug Market mainly focuses on the outlook and status for top Androgenic Alopecia Drug applications/end users, Androgenic Alopecia Drug market size, Share, consumption (sales), sales volume and growth rate for each application, including; Clinic, Hospital, HomeUse.

This Androgenic Alopecia Drug Market 2018 Study Report offers:

• A review of The Worldwide market for Global Androgenic Alopecia Drug Market and related advancements.
• In-depth analyses of Global market trends, with data from 2013, estimates for 2014 and 2017, and prediction of CAGR through 2023.
• A Clear Forecast prospect for geographical segments (regions) and also sub-segments will extend at the most exalted rate.
• Essential techniques for growth, and the demand for new applications and new products.
• Brand Procedure, Target Clients and Pricing Technique.
• Competitive landscaping of key market players.

List of Chapters (TOC) of Global Androgenic Alopecia Drug Market 2018 Study Report Contains the Following Points:

Chapters 1. Androgenic Alopecia Drug Industry Overview.
Chapters 2. Worldwide Androgenic Alopecia Drug Market Competition by Prime Players/Providers, Product Type, and Application.
Chapters 3. United States Androgenic Alopecia Drug Market Share and Androgenic Alopecia Drug Sales Volume by Key Players, Product Type & Application.
Chapters 4. Europe Androgenic Alopecia Drug Market Share, Growth Rate, & Sales.
Chapters 5. India Androgenic Alopecia Drug (Deals Cost, Value and Volume).
Chapters 6. China Androgenic Alopecia Drug Industry (Sales Price, Value and Volume).
Chapters 7. Japan Androgenic Alopecia Drug Marketplace Growth Rate, Sales Price Trend, Income.
Chapters 8. South-east Asia Androgenic Alopecia Drug Market (Sales Price, Value and Volume).
Chapters 9. Global Androgenic Alopecia Drug Providers/Players Profiles and Deals Information.
Chapters 10. Production Cost Analysis of Androgenic Alopecia Drug business.
Chapters 11. Androgenic Alopecia Drug Downstream Consumers, Sourcing Method, Industrial Chain.
Chapters 12. Worldwide Androgenic Alopecia Drug Traders/Distributors, Marketing Strategy Analysis.
Chapters 13. Androgenic Alopecia Drug Industry Impact Factors Analysis.
Chapters 14. Worldwide Androgenic Alopecia Drug Market Forecast (2018-2023).
Chapters 15. Worldwide Androgenic Alopecia Drug Market Research and Development Status, Research Findings and Conclusion.
Chapters 16. Appendix.

Ask Full Table of Content (TOC) with Graphs, Figures, Tables Here: http://www.qymarketresearch.com/

Global Androgenic Alopecia Drug Market 2018

Source

Global Alopecia Drugs Market Insights Report

Alopecia pipeline review

Alopecia pipeline review H2 2018 just published

If you are want to study the Alopecia industry or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players.

If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body.

Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Key Players included in the research study are Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA, Concert Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dong-A Socio Holdings Co Ltd, Eli Lilly and Co, Energenesis Biomedical Co Ltd, Follica Inc, Histogen Inc, Japan Tobacco Inc, JW Pharmaceutical Corp, Kuhnil Pharmaceutical Co Ltd, Lee’s Pharmaceutical Holdings Ltd, Medivir AB, NovaLead Pharma Pvt Ltd, OliX Pharmaceuticals Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Quark Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Samumed LLC, Taisho Pharmaceutical Holdings Co Ltd & Tigo GmbH.

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Alopecia pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision-making capabilities and helps to create effective marketing strategies to gain a competitive advantage in healthcare and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real-time basis.

Extracts of Chapters from Alopecia – Pipeline Review, H2 2018
Chapter 1, to describe the definition, overview and Therapeutics Development of Alopecia.
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes.
Chapter3, Therapeutics Assessment of Alopecia by Target, Mechanism of Action, Route of Administration and by Molecule Type.
Chapter4, to display company profile involved in Therapeutics Development.
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Alopecia.
Chapter 6,7, to describe Alopecia Appendix, Methodology, Coverage, Secondary Research, Primary Research, Expert Panel Validation and Contact Us.

Objective of this study

– To provides a snapshot of the global therapeutic landscape of Alopecia.
– To reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alopecia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews the latest news related to pipeline therapeutics for Alopecia

This research report helps to

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Alopecia.
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alopecia pipeline review

Source

barber alopecia hair loss

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

The Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss and Refer for Medical Treatment

SKIN: The Journal of Cutaneous Medicine® Article-Scarring Alopecia: The Attitudes, Knowledge, and Referral Patterns of Hair Stylists and Barbers

Training hairdressers in hair loss screening and patient education present a promising opportunity for early detection and treatment of potentially irreversible hair loss.”

Disorders of hair loss affect a large portion of the population. A group of hair loss disorders known as “scarring alopecia” or scarring hair loss presents a particular challenge to patients and physicians.

This type of alopecia, which affects up to 3% of people suffering from hair loss, is associated with inflammation that causes scar tissue to replace hair follicles. This often results in permanent hair loss.

Early diagnosis and treatment by an expert are extremely important in ensuring positive outcomes.

However, it is not uncommon for patients with scarring alopecia to have a delayed presentation to medical care, often because they are unaware of the differences between this entity and the more common male- and female-pattern hair loss.

Hairdressers and barbers encounter customers with hair loss on a near-daily basis and thus are uniquely positioned to help identify scarring alopecia early in the disease course.

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

In an article published in SKIN: The Journal of Cutaneous Medicine®, Julia Accetta, BS, and coauthors from the Department of Dermatology at the Tulane University School of Medicine investigated the knowledge and attitudes of hair stylists with regards to scarring alopecia.

Accetta and her team surveyed 118 stylists and found that the majority had been asked by clients to evaluate for hair loss, whereas about half reported routinely referring clients with hair loss to a dermatologist expert.

Further, the authors noted that although stylists’ knowledge of scarring hair loss varied, around 80% stated that they would be willing to undergo specific training to allow them to better identify specific hair loss disorders and to discuss this with their clients.

According to Accetta, “training hairdressers in hair loss screening and patient education presents a promising opportunity for early detection and treatment of potentially irreversible hair loss.”

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

For more details please visit www.jofskin.org

Potential of Hairstylists and Barbers to Identify Disorders of Hair Loss

Source

Alopecia Market Growth Opportunities

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

Aclaris Therapeutics, Inc, a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced positive interim data from its Phase 2 clinical trial (AA-202 Topical) of ATI-502 for the treatment of Alopecia Totalis (AT) or Alopecia Universalis (AU), the more severe variants of Alopecia Areata (AA).

ATI-502, an investigational topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502) is the most advanced topical JAK inhibitor in clinical trials for AT/AU in the United States.

This randomized, double-blind clinical trial is being conducted at 2 study sites and will evaluate the pharmacokinetics, pharmacodynamics, and safety of ATI-502 compared with vehicle in 11 patients with AT or AU over 28 days of treatment, followed by a 6-month open-label period when all patients receive the drug.

AA is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body. More severe forms of AA are characterized by a total scalp hair loss (AT) or total hair loss on the scalp and body (AU).

Today, we report interim results for 6 of the 11 enrolled patients; data from the full cohort will be reported in the future.

Pharmacokinetic Results:

Systemic exposure was low as indicated by plasma drug levels that were below the limits of quantification (1ng/ml) in all subjects at day 28.
• Consistent with low systemic exposure, no significant changes in circulating T, B and NK cells were observed at day 28.
To assess skin penetration, punch biopsies were obtained at baseline and day 28 which demonstrated topical ATI-502 absorption consistent with pre-clinical skin models.
• Mean of 5650 nanograms/gram at day 28 (range 3130 – 8170 ng/g).
Pharmacodynamic / RNA Sequencing Results:

2 patients had marked elevation of the interferon gamma and cytotoxic T-cell gene expression signatures at baseline: one received active drug and one received vehicle. At day 28, the patient on active drug demonstrated a positive change in the 2 biomarkers, while the patient on vehicle did not demonstrate a positive change in the 2 biomarkers.
2 patients had low elevation of the interferon gamma and cytotoxic T-cell gene expression signatures at baseline: one received active drug, one received vehicle. At day 28 both patients showed a partial positive change in the 2 biomarkers.
2 patients had no elevation of the interferon gamma and cytotoxic T-cell gene expression signatures at baseline: both patients received active drug. At day 28, neither patient showed any material change in the 2 biomarkers.
Safety

No serious adverse events (SAEs) were reported during the 28-day dosing period. One subject receiving ATI-502 withdrew from the trial due to an unrelated SAE of major depression during the open-label extension period.
Key Results Summary

This data is the first indication that ATI-502 is absorbed through the human skin in the clinical setting and engages the target. The results also demonstrate the pharmacodynamic effect of modulating the appropriate genes associated with the interferon-gamma pathway and cytotoxic T-lymphocytes, which are 2 of 3 biomarker components of the Alopecia Areata Disease Activity Index (ALADIN) score.

Our hypothesis is this response can be predicted by a patient’s baseline genetic signature.

“This is the first time we have demonstrated that Topical ATI-502 is positively impacting the genetic signature implicated in alopecia areata,” said Stuart Shanler, M.D., Chief Scientific Officer of Aclaris Therapeutics, Inc.

Aclaris Therapeutics topical ATI-502

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

Onset of the disease can occur throughout life and affects both women and men. AA can be associated with serious psychological consequences, including anxiety and depression. AA affects up to 2.0% of people globally at some point during their lifetime (i.e. incidence) and up to 0.2% of people are affected at any given time (i.e. prevalence). There are currently no drugs approved by the FDA for the treatment of AA.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ clinical development of its JAK inhibitor drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2017, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “Financial Information” section of the Investors page of Aclaris’ website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502

Source

Aclaris Therapeutics topical ATI-502

 

Global Alopecia Drugs Market Insights Report

Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia

Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

Aclaris Therapeutic, a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced that the first patient has been dosed in Aclaris’ Phase 2 clinical trial of its JAK inhibitor product candidate ATI-501 oral suspension in patients with two forms of Alopecia Areata (AA) known as Alopecia Totalis (AT) and Alopecia Universalis (AU).

AA is an autoimmune dermatologic condition typically characterized by patchy non-scarring hair loss on the scalp and body. More severe forms of AA include AT, which is total scalp hair loss, and AU, which is total hair loss on the scalp and body.

This multicenter, randomized study, known as AUAT-201, will evaluate the safety, tolerability, and efficacy of ATI-501 oral suspension for the treatment of AU or AT in adult subjects. Aclaris intends to enroll approximately 80 subjects with a clinical diagnosis of stable AU or AT. Enrolled subjects will receive either ATI-501 or placebo for 6 months.

The primary efficacy endpoint is the mean change from baseline in the Severity of Alopecia Tool (SALT) score at Week 24. Secondary and exploratory endpoints include the change from baseline in the Alopecia Density and Extent Score (ALODEX) score and various clinician and patient-reported outcomes.

“This trial is the first step in evaluating the potential clinical benefit of ATI-501 oral suspension in treating patients with the alopecia totalis and alopecia universalis forms of alopecia areata,” said Dr. Stuart Shanler, Chief Scientific Officer of Aclaris. “This is an important step forward in understanding the clinical utility of our JAK inhibitors in patients with AA.”

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology.

Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp.

The onset of the disease can occur throughout life and affects both women and men. AA can be associated with serious psychological consequences, including anxiety and depression.

AA affects up to 2.0% of people globally at some point during their lifetime (i.e. incidence) and up to 0.2% of people are affected at any given time (i.e. prevalence). There are currently no drugs approved by the FDA for the treatment of AA.

Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia

Source

Alopecia Market Pipeline Revive H1 Therapeutics

Hair Loss and Balding in Women

Hair Loss and Balding in Women

Hair Loss and Balding in Women: Lilac Corp Reviews a Study and Recommends Nolopecia for Hair Growth in Women

All natural hair loss supplement sold by Lilac Corp —

Lilac Corp discusses a study on a new discovery that links the ANGPT2 gene and hair loss and recommends Nolopecia, a natural treatment for hair growth in women.

There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause an increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.”

Female pattern hair loss is a specific type of hair loss that is common in postmenopausal women. Menopause causes a change in a woman’s hormones, leading to a decrease in estrogen. Estrogen supplementation has been shown to increase hair growth in postmenopausal women.

However, estrogen supplementation has serious side effects, and scientists aren’t sure how exactly it works to increase hair growth. To study the link between estrogen and balding in women, researchers removed the ovaries of female mice, causing the mice to go through menopause and have hair loss [1].

Then they measured the expression of different genes in these mice. The scientists noticed a decrease in the expression of a gene called ANGPT2, which is controlled by the estrogen hormone. The researchers then supplemented the mice with the protein expressed by the ANGPT2 gene.

The results showed hair regrowth after only 24 days.

Interestingly, higher doses of the protein resulted in more hair growth. The researchers concluded that the protein expressed by the ANGPT2 gene can reverse hair loss in postmenopausal mice.

For women who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. The new treatment targets the latent viruses in the body.

This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth. There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin.

For more information on these products, see lilaccorp.com.

See also references below.

About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Sources:
[1] Endo, Y., Obayashi, Y., Ono, T., Serizawa, T., Murakoshi, M., & Ohyama, M. (2018). Reversal of the hair loss phenotype by modulating the estradiol-ANGPT2 axis in the mouse model of female pattern hair loss. Journal Of Dermatological Science. doi: 10.1016/j.jdermsci.2018.04.001

[2] Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016 Aug 29;10:2713-22

[3] Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.

[4] Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 Mar 3; 11:575-583

Source

Scientific Advances to Treating Womens Scalp Conditions

Progress of Federal Taxotere Hair Loss Lawsuits

Taxotere Permanent Alopecia Allegations

JPML Refuses to Vacate Order Transferring Taxotere Lawsuit to Federal Hair Loss Litigation in Louisiana

The U.S. Judicial Panel on Multidistrict Litigation (JPML) continues to transfer Taxotere lawsuits to the U.S. District Court, Eastern District of Louisiana, where all federally-filed product liability claims involving the medication’s alleged association with permanent hair loss have been centralized for the purpose of coordinated pretrial proceedings.

According to an Order dated October 4th, the JPML has refused to vacate the conditional transfer of one such case, despite the plaintiff’s arguments that (1) federal subject matter jurisdiction is lacking; (2) plaintiff’s motion for remand to state court is pending; and (3) transfer would cause her undue delay.

The case was initially filed in Delaware state court, and later removed to the U.S. District Court, District of Delaware, before being conditionally transferred to the federal Taxotere litigation in Louisiana.

In refusing to vacate its conditional transfer order, the JPML noted that jurisdictional issues do not present an impediment to transfer, as plaintiffs can present their arguments to the transferee judge.

The Panel also disputed that any resulting delay made transfer unwarranted, as such a transfer is appropriate if it furthers the expeditious resolution of the litigation as a whole.

Taxotere Hair Loss

Taxotere Permanent Alopecia Allegations

Taxotere is manufactured by Sanofi-Aventis and was approved to treat breast cancer by the U.S. Food & Drug Administration (FDA) in 1996. The chemotherapy drug has since been approved to treat other cancers, including head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer.

More than 1,600 Taxotere lawsuits have been centralized in the multidistrict litigation now underway in the District of Louisiana. All of the pending cases were filed on behalf of cancer patients who allegedly experienced permanent alopecia (hair loss) following treatment with Taxotere.

While hair loss is a typical side effect of chemotherapy, plaintiffs involved in the Taxotere litigation allege that alopecia associated its use is more likely to be permanent compared to hair loss that accompanies treatment with other, equally effective medications.

Among other things, plaintiffs point out that the European medical community was informed of the potential for permanent hair loss in 2005, while the Canadian Taxotere label underwent a similar modification in 2012. However, mention of permanent alopecia was not included on the U.S. Taxotere label until December 2015.

Why Were Taxotere Lawsuits Centralized in Louisiana?

The JPML established the federal Taxotere litigation in October 2016, initially transferring just 33 lawsuits to the Eastern District of Louisiana.

The multidistrict litigation process allows cases of a similar nature to undergo coordinated discovery and other pretrial proceedings, and is intended to improve judicial efficiency by preventing duplicative proceedings, eliminating inconsistent court rulings, and preserving the resources of the courts, parties, and witnesses involved in the litigation.

The Eastern District of Louisiana is scheduled to convene its first trial involving a Taxotere lawsuit in January 28, 2019. As a bellwether trial, its outcome could provide insight into how other juries will decide similar Taxotere hair loss claims.

The case will be followed by three additional bellwether trials, which are scheduled to be convened on April 8, 2019, July 15, 2019, and November 4, 2019

Source

alopecia research

Global Alopecia Drugs Market to increase rapidly by 2022

Global Alopecia Drugs Market to increase rapidly by 2022

Alopecia Drugs Industry, 2012-2022 Market Research Report’ is a professional and in-depth study on the current state of the global Alopecia Drugs industry with a focus on the Chinese market.

The report provides key statistics on the market status of the Alopecia Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.

Browse complete report at www.researchtrades.com/report/global-and-chinese-alopecia…

Through the statistical analysis, the report depicts the global and Chinese total market of Alopecia Drugs industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2017-2022 market development trends of Alopecia Drugs industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Alopecia Drugs Industry before evaluating its feasibility.

Overall, the report provides an in-depth insight of 2012-2022 global and Chinese Alopecia Drugs industry covering all important parameters.

Chapter One Introduction of Alopecia Drugs Industry

1.1 Brief Introduction of Alopecia Drugs
1.2 Development of Alopecia Drugs Industry
1.3 Status of Alopecia Drugs Industry

Chapter Two Manufacturing Technology of Alopecia Drugs

2.1 Development of Alopecia Drugs Manufacturing Technology
2.2 Analysis of Alopecia Drugs Manufacturing Technology
2.3 Trends of Alopecia Drugs Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers

3.1 Company A
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 2012-2017 Production Information
3.1.4 Contact Information
3.2 Company B
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 2012-2017 Production Information
3.2.4 Contact Information
3.3 Company C
3.2.1 Company Profile
3.3.2 Product Information
3.3.3 2012-2017 Production Information
3.3.4 Contact Information
3.4 Company D
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 2012-2017 Production Information
3.4.4 Contact Information
3.5 Company E
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 2012-2017 Production Information
3.5.4 Contact Information
….
Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

We distribute customized reports that focus on meeting the client’s specific requirement. Our database consists of a large collection of high-quality reports obtained using a customer-centric approach, thus providing valuable research insights.

Source

Global Alopecia Drugs Market to increase rapidly by 2022

Alopecia Awareness Week

Alopecia Awareness Week

Alopecia Awareness Week: How wigs can help children with the condition feel more confident

STELLA Hammet was five years old when her hair started falling out.

The 12-year-old from Melbourne has alopecia, a rare auto-immune disease where the body’s immune system attacks the hair follicles. There is no cure and most sufferers are diagnosed before their 20th birthday.

“I remember my mum was brushing my hair one day and my hair sort of came out in clumps in the sink. I said ‘Oh no, what’s happening?’ because I didn’t know what it was,” Stella told news.com.au.

“It started coming off in patches around the back of my head, so I wore bandannas and scarves to try and cover them up. But then the patches got bigger and then it all fell off. It felt like one day I just woke up with no hair.”

By the time she was seven, Stella was completely bald.

During Alopecia Awareness Week, the charity organisation Variety is raising awareness about its Wigs for Kids program, which funds wigs for children who have lost their hair.

Wigs made from human hair can cost $4000-$6000 (it takes 10-15 ponytails to create a single wig) but after 18 months they start to lose their hair. These handmade, custom wigs come fitted with a silicon cap to prevent itching.

Stella, who is now onto her third wig, says being able to walk down the street without attracting stares is a welcome relief.

“I just get up, put my wig on and go to school. It’s just normal now and it’s actually quite easy to style,” she said.

“I just do it on the wig stand. If you do it up too high you can see the edges, so I mainly wear it in a low pony.”

Stella’s father Andrew Hammet also has alopecia and lost his hair at age 16.

“Because Dad was a kid when his hair started falling out, I’ve always known him with no hair,” Stella said. “I’ve seen photos of him at my grandparents’ house with hair and I just thought ‘Oh, that’s weird’.”

Mr Hammet said he never expected his condition would be passed onto his daughter.

“I just thought it was a one-off thing that would only affect me,” said Mr Hammet. “When her hair started falling out I thought ‘I know exactly what’s going to happen’, which is depressing because I knew the treatments are mostly ineffective.”

He says it was heartbreaking to see his daughter feel insecure and embarrassed about her appearance.

“Adults often think kids aren’t aware of how they look and see themselves, but we soon realised that Stella didn’t like looking at herself,” he said.

“One time my wife and I went into her bedroom and she had scrawled lipstick all over her mirror in her bedroom. We said ‘What did you do that for?’ and we realised it was because she didn’t want to look at herself.”

Before Stella got her first wig in Year 3, she felt awkward around her classmates.

“Everyone else was like ‘I’m going to get a fringe tomorrow’ and I couldn’t really do that,” she said. “When I was wearing my bandannas people called me a boy.”

Mr Hammet says there were rumours flying school around about why Stella’s hair had fallen out.

“Kids were saying things like ‘Oh my god, Stella’s got cancer!’ and we wanted to address that,” he said.

So when Stella arrived at high school, she went on the front foot and decided to be open about her condition.

“I told everyone in my class,” she said. “I made a powerpoint presentation with photos, explaining what alopecia is. Everyone was really accepting, asked lots of questions. and nobody thought of me any differently.

“I thought if I didn’t do that, it would be really hard with things like sleepovers, because everyone would look at me like ‘What’s wrong with her?’ Now they say to me ‘Hey Stella, how’s your hair going?’”

Dr Anne Halbert from the department of paediatric dermatology at Princess Margaret Hospital says hair loss can be especially distressing for children.

“Many children who are diagnosed with alopecia face a devastating reality. Hair loss can have aprofound negative psychological impact on them due to self-imposed isolation from normal day-to-day life,” said Dr Halbert.

“A specialised wig can allow kids with hair loss to live a normal life, relieving much of the exclusion they can feel.”

The Variety Wigs for Kids program provides specialised wigs to kids whose parents can’t afford to buy one.

“One specialised can wig cost up to $6000 and lasts two to three years so the cost is prohibitive for many families,” said Variety CEO Tam Johnston.

“The wigs are fitted to each child’s head, with customised colour, length and style. This program is just one of the many ways Variety helps kids who are sick, disadvantaged or have special needs.”

To donate your hair or to apply for wig funding visit variety.org.au

National Alopecia Areata Foundation

Source

alopecia report

Asia Pacific Alopecia Treatment Market

Asia Pacific Alopecia Treatment Market to Reach US$ 2,655.9 Mn by 2024, Driven by Increasing Prevalence of Chemotherapy Induced Alopecia By PMR

According to a latest market report published by Persistence Market Research, titled Asia Pacific Alopecia Treatment Market 🙁 2016-2024)”, revenue from the Asia Pacific alopecia treatment market is expected to expand at a CAGR of 6.6% during the forecast period 2016-2024.

In the report, the Asia Pacific alopecia treatment market is analyzed on the basis of, type of alopecia, treatment type, and end user.

On the basis of type of alopecia, the overall market has been segmented into alopecia areata, alopecia totalis, and alopecia universalis.

Topical drugs (creams, oils, lotions, gels, shampoos, and foam), oral drugs, injectable (platelet rich plasma therapy, steroid and injectable fillers), hair transplant services and low level laser therapy form the basis of treatment type.

By end user segment, the market has been segmented into hospitals, dermatology and trichology clinics, home care settings, and aesthetic clinics.

In the overall market, oral solid dosage formulations are expected to witness increased acceptance owing to ease of consumption by patients in Asia Pacific. Accordingly, oral drugs segment is anticiapted to witness an increase in value from US$ 556.6 Mn in 2016 to US$ 1,005.1 Mn by the end of 2024.

Rising global demand for effective hair loss treatment medications especially oral drugs is the prime driver of the market.

Oral hair loss treatment drugs are gaining popularity as they help in maintaining patient-safety through reduced number of medicine dosages, but with increased drug efficacy.

However, changing lifestyle along with increase in stress level among working class population, cosmeceutical drug manufacturers focusing on expanding their hair treatment and scalp treatment product line, and cytokine therapy gaining momentum for alopecia treatment are other factors that expected to fuel the market growth for alopecia treatment market over the forecast period.

Patent expiry of major blockbuster drugs resulting in market exclusivity for some brands and various side effects associated with the hair loss treatments is expected to hamper the overall market growth.

Some of the side effects such as allergies, depression, and chances of permanent sexual dysfunctions.

Other market deterrents include limited efficacy of the hair loss treatment drugs and lack of reimbursement facilities for hair loss treatments services, such as laser treatments.

Based on countries, the market has been divided into China, Japan, Australia & New Zealand, Malaysia, Singapore, India, Vietnam, Philippines and Rest of Asia Pacific.

Developed pharmaceuticals markets such as the China and Japan are expected to emerge as the main sourcing markets.

To View and Download TOC: http://www.persistencemarketresearch.com/market-research/asia-pacific-alopecia-treatment-market/toc

This report assesses trends by type of alopecia, treatment type, end user, and countries; to offer analytical insights about the potential demand emerging for particular alopecia treatments in specific regions.

China is estimated to dominate the alopecia treatment market accounting for maximum revenue share of the overall market by end of 2016.

By 2024 end, China and Japan markets are expected to account for over three-fifth share of the Asia Pacific alopecia treatment market revenue. In terms of market share by value, China is estimated to retain its dominant position, registering a CAGR of 7.1% over the forecast period.

Some key companies covered in this report include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd.

These companies are primarily focused on enhancing their product portfolio through research and development and introduction of innovative and cost-effective advanced manufacturing procedures in order to gain higher market share and to strengthen their respective positions in the Asia Pacific market.

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  •  Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.

About Us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources.

By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Source